Blood Pressure Management
Discover our Therapy
ARC Therapy is targeted, programmed stimulation of the spinal cord designed to restore movement, function, and independence after spinal cord injury (SCI).
In addition to restoring movement after SCI, ARC Therapy has the potential to regulate blood pressure and help with symptoms of hemodynamic instability, such as fatigue or lightheadedness.
Implantable Platform
Implantable Platform
-
Investigational, implantable neurostimulation platform to minimally invasively deliver targeted ARCIM Therapy to the spinal cord.
The US FDA awarded the ARCIM platform Breakthrough Device Designations for restoration of leg motor function, blood pressure regulation, trunk stabilization, bladder control, and alleviation of spasticity in people with spinal cord injury.
Learn more
We are also advancing brain-computer interface (BCI) technology to restore thought-driven movement after SCI when used with our ARCIM platform.
Improved Blood Pressure Regulation
ARCIM is the first neuroprosthetic system designed to reduce the symptoms related to Orthostatic and Postprandial Hypotension and Autonomic Dysreflexia (AD) in people living with chronic spinal cord injury (SCI) at lesion level C3-T6 AIS A-D.
We received FDA Breakthrough Device Designation for ARCIM in 2020 to normalize blood pressure.
Read our Publications
-
-
A neuronal architecture underlying autonomic dysreflexia
Nature
-
Safety and Effectiveness of Multisite Transcutaneous Spinal Cord Stimulation Combined With Activity-Based Therapy When Delivered in a Community Rehabilitation Setting: A Real-World Pilot Study
Neuromodulation
-
Non-invasive spinal cord electrical stimulation for arm and hand function in chronic tetraplegia: a safety and efficacy trial
Nature Medicine
-
A spinal cord neuroprosthesis for locomotor deficits due to Parkinson’s disease
Nature Medicine
-
Walking naturally after spinal cord injury using a brain–spine interface
Nature
Please complete this form to
contact us or receive updates
The ONWARD® Medical ARCEX® System is FDA cleared for use in the United States and CE marked in accordance with EU Medical Device Regulation 2017/745. ONWARD ARCIM® and ARCBCI™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
Indication for Use (US): The ARCEX® System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old who present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).
Indication for Use (EU): The ARCEX® System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic and with take-home exercises in the home to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).